Effect of dopamine & amine-oxidase inhibitors in experimental myocardial infarction in rats.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A K Basu.
Explore the source record for details and available documents.
Two cases of chronic lymphocytic leukaemia are presented in which, in the terminal phase of the disease, a population of abnormal lymphocytes similar to those seen in lymphosarcoma cell leukaemia replaced the morphologically normal small lymphocytes observed previously. Immunologically, this change coincided with a striking alteration in the pattern of surface immunoglobulin markers. In both cases, most cells initially carried IgM and in both cases these were replaced by cells carrying IgG as the number of abnormal lymphocytes increased. In addition, the use of anti-delta antiserum in the second case revealed the coexistence of large numbers of IgD-bearing lymphocytes as well. Calculations showed that more than half the cells present at that time must have been carrying both IgD and IgG surface markers.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The conventional radioisotope scanner has been used as a whole body counter. The background index of the system is 10.9 counts per minute per ml of sodium iodide crystal. The sensitivity and derived sensitivity parameters have been evaluated and found to be suitable for clinical studies. The optimum parameters for a single detector at two positions above the lying subject have been obtained. It has been found that for the case of 131I measurement it is possible to assay a source located at any point in the body with coefficient of variation less than 5%. To add to the versatility, a fixed geometry for in-vitro counting of large samples has been obtained. The retention values obtained by the whole body counter have been found to correlate with those obtained by in-vitro assay of urine and stool after intravenous administration of 51Cr-albumin.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.